Fig. 5
From: Maraviroc/cisplatin combination inhibits gastric cancer tumoroid growth and improves mice survival
Tumoroid formation. (A) Scheme of development of tumoroids from AGS-RCDDP cells. (B) Representative images of tumoroids (3D tumor spheroids) on day 24. (C) Tumoroids number after treatments with MVC and/or CDDP. (D) Tumoroids size after treatments with MVC and/or CDDP. Tumoroids with a size > 100 μm were quantified. The size bar corresponds to 100 μm. Tumoroid formation and size were analyzed using one-way ANOVA with Tukey´s multiple comparisons post-hoc test. Values of P ≤ 0.05 were considered statistically significant. *P ≤ 0.05, **P < 0.01, ****P < 0.0001. Data were expressed as mean ± SD of three biological replicates. Maraviroc (MVC) and Cisplatin (CDDP)